Compare UONEK & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UONEK | NEUP |
|---|---|---|
| Founded | 1980 | 1996 |
| Country | United States | United States |
| Employees | 1272 | 8 |
| Industry | Broadcasting | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.8M | 23.8M |
| IPO Year | N/A | N/A |
| Metric | UONEK | NEUP |
|---|---|---|
| Price | $5.06 | $4.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 16.8K | ★ 27.8K |
| Earning Date | 05-14-2026 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $3.65 |
| 52 Week High | $9.38 | $21.31 |
| Indicator | UONEK | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 43.09 | 39.66 |
| Support Level | $4.75 | $3.85 |
| Resistance Level | $6.12 | $4.94 |
| Average True Range (ATR) | 0.64 | 0.21 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 17.14 | 25.00 |
Urban One Inc is an urban oriented, multi-media company. Its business is radio broadcasting franchise that is the radio broadcasting operation that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment includes all the broadcasting related operations. The Reach Media segment consists of the Tom Joyner Morning Show and its related activities. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One's operations.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.